Clinical Trial: Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin''s Lymphoma

This study is not yet open for patient recruitment.
Verified by National Cancer Institute (NCI) December 2005

Sponsors and Collaborators: North American Brain Tumor Consortium
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI) Identifier: NCT00248534


RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as temozolomide and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Rituximab may help chemotherapy kill more cancer cells by making cancer cells more sensitive to the drugs. Giving rituximab together with temozolomide and methylprednisolone may be an effective treatment for primary CNS non-Hodgkin''''s lymphoma.

PURPOSE: This phase II trial is studying how well giving rituximab together with temozolomide and methylprednisolone works in treating patients with recurrent primary CNS non-Hodgkin''''s lymphoma.

Condition Intervention Phase
Primary Central Nervous System Lymphoma
 Drug: methylprednisolone
 Drug: rituximab
 Drug: temozolomide
 Procedure: antibody therapy
 Procedure: biological response modifier therapy
 Procedure: chemosensitization/potentiation
 Procedure: chemotherapy
 Procedure: monoclonal antibody therapy
Phase II

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Rituximab, Temozolomide, and Methylprednisolone in Patients With Recurrent Primary CNS Non-Hodgkin''''s Lymphoma

Further study details as provided by National Cancer Institute (NCI):




OUTLINE: Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 and oral temozolomide daily on days 1-7 and 15-21. After day 28, patients with stable disease or better proceed to consolidation therapy.

Patients receive oral temozolomide daily on days 1-5. Treatment repeats every 28 days for up to 6 courses. Patients achieving a complete remission proceed to maintenance therapy.

Patients receive methylprednisolone IV over 2 hours on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within approximately 13.3 months.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


  • Histologically confirmed primary CNS non-Hodgkin''''s lymphoma
  • Recurrent disease
  • Radiographical evidence of tumor progression by MRI or CT scan
  • Steroid therapy must be stable for 5 days prior to scan



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • More than 8 weeks


  • WBC ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10 g/dL (transfusion allowed)


  • SGOT < 2 times upper limit of normal (ULN)
  • Bilirubin < 2 times ULN
  • No active or latent hepatitis B infection


  • Creatinine < 1.5 mg/dL OR
  • Creatinine clearance ≥ 60 mL/min


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No uncontrolled significant medical illness that would preclude study treatment
  • No active infection
  • No concurrent disease that would dangerously alter drug metabolism or obscure toxicity


Biologic therapy


  • No prior temozolomide
  • At least 14 days since prior methotrexate
  • At least 21 days since prior procarbazine
  • At least 42 days since prior nitrosoureas
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 7 days since prior tamoxifen
  • No concurrent hormonal therapy


  • No concurrent radiotherapy


  • Not specified


  • Recovered from all prior therapy
  • At least 28 days since prior investigational agents
  • At least 28 days since other prior cytotoxic therapy
  • At least 7 days since other prior non-cytotoxic agents (e.g., tretinoin) (radiosenitizers allowed)
  • No other concurrent investigational drugs

Location and Contact Information

Please refer to this study by identifier  NCT00248534

Study chairs or principal investigators

Lauren E. Abrey, MD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute''''s PDQ® database

Study ID Numbers:  CDR0000445289; NABTC-05-01
Last Updated:  December 6, 2005
Record first received:  November 3, 2005 Identifier:  NCT00248534
Health Authority: United States: Federal Government processed this record on 2006-01-10


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us